ERBB2 and breast cancer: A major subtype, triple-negative breast cancer (TNBC), is characterized by the lack of expression of estrogen receptor (ER), progesterone receptor (PR), and HER2 (ERBB2), and accounts for approximately 15 % of all breast cancer cases (Waks and Winer, 2019).